The nervous system carries electrical impulses – or action potentials – which control virtually every organ or function in our bodies. Bioelectronic medicine is an emerging therapeutic field which aims to control these electrical signals in nerves via minimally or non-invasive devices to treat a range of debilitating chronic diseases.
We are a fund dedicated to advancing bioelectronic medicines and are looking to invest in high-return opportunities in three areas:
Teams pursuing new indications for existing peripheral neurostimulation devices.
Teams developing novel bioelectronic technologies for established neuromodulation targets.
Advanced technologies that enable the future of targeted and minimally invasive bioelectronic medicines.
We are a small dedicated team that is backed by GlaxoSmithKline but remains firewalled from the company. We are able to lead investments into start-ups, are stage agnostic, seek no strategic rights and once invested behave like a traditional financial investor following on our investments and remain well-aligned with other institutional VCs around the board.